Evaluation of toxic effects following administration of monoclonal antibody MBr1 in patients with breast cancer.


Twelve patients with disseminated breast cancer were injected with monoclonal antibody MBr1 at the National Cancer Institute of Milan, Italy, from January 1983 to March 1985. The first seven patients had advanced disease and the remaining five operable breast cancer. In the first seven patients the initial dosage of MBr1 was 0.5 mg and was doubled in the… (More)


  • Presentations referencing similar topics